3 month follow up reportWith summary of the other evaluation reports Table of contents Learner demographics Learner satisfaction Scientific programme Event organisation Teaching effectiveness Learning effectiveness Immediate post-event survey results compared to pre-event survey results Three month follow up results Learner demographics Learner demographics – Profession
Dans la pharmacie en ligne Viagra-représenté Paris large éventail de la dysfonction érectile anti-plus consommée. Générique Levitra (vardenafil), Cialis (tadalafil) et achat viagra pour homme, dont le prix est acceptable pour tous les budgets.1
Yo no soy un gran amante de pedir medicamentos por internet. Pero a veces la necesidad de herramientas, que en las farmacias regulares o no, o rara vez levitra comprar Recibes como un paquete, todo montado y embalado.
Microsoft word - cv_nina_tunariu_august15_romana.docDr. NINA TUNARIU MDC MRCP FRCR MDRES Consultant Radiologist (Medic Primar) Royal Marsden Hospital NHS Foundation Trust , Londra, Marea Britanie Specialitatea mea este Imagistica Oncologica (7 ani vechime) cu focus in evaluarea efectelor anti- tumorale bazata pe CT si RMN utilizand criterii imagistice internationale si diagnosticare efectelor toxice ale tratamentelor oncologice. Responsabilitatile mele zilnice include imagistica oncologica de rutina (CT, RMH, ecografie - 1400CT & 750RMN & 600 ecografii anual). Deasemenea am un interes special in imagistica pacientilor inclusi in tratament experimentale (trialuri clinice), cancere ginecologice si urologice. Calificari Profesionale: MDRes (Cercetare) University of London Fellowship Royal College of Radiologists Membru Royal College of Physicians Diploma Licenta in Medicina Generala Universitatea de Medicina si Farmacie "Iuliu Hatieganu" Cluj-Napoca, Romania "Standardizarea methodelor de analiza ale RMN-lui Multiparametric"- October 2013 Specializarea in Radiologie: Specializare Imagistica Oncologica Oct '08 – Aug'13 Institute of Cancer Research & Royal Marsden Hospital, Londra Rezident Radiologie Sept ‘04 – Oct ‘08 KSS Deanery Radiology Training Scheme Imperial College HealthCare NHS Trust, Londra Rezident Radiologie April ‘99 – Oct‘00 Spitalul Judetean Brasov Experienta in Medicina Royal London Hospital Feb ‘04 – Aug ‘04 Papworth Hospital, Cambridge Medicine Toracica Oct ‘03 – Feb ‘04 Hammersmith Hospitals, Londra Aug ‘03 –Oct ‘03 Hammersmith Hospitals, Londra Medicina Generala Nov '01 - July ‘03 Spitalul Judetean Brasov Medicina de Familie Jan ‘98 – April'99 1. Serial Next Generation Sequencing of Circulating Cell Free DNA Evaluating Tumour Clone Response To Molecularly Targeted Drug Administration. Frenel JS, Carreira S, Goodall J, Roda Perez D, Perez Lopez R, Tunariu N, Riisnaes R, Miranda S, Figueiredo I, Nava Rodrigues D, Smith A, Leux C, Garcia-Murillas I, Ferraldeschi R, Lorente D, Mateo J, Ong M, Yap TA, Banerji U, Gasi Tandefelt D, Turner N, Attard G, de Bono JS. Clin Cancer Res. 2015 Jun 17. pii: clincanres.0584.2015. [Epub ahead of print]. 2. Integrative clinical genomics of advanced prostate cancer. Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, Montgomery B, Taplin ME, Pritchard CC, Attard G, Beltran H, Abida W, Bradley RK, Vinson J, Cao X, Vats P, Kunju LP, Hussain M, Feng FY, Tomlins SA, Cooney KA, Smith DC, Brennan C, Siddiqui J, Mehra R, Chen Y, Rathkopf DE, Morris MJ, Solomon SB, Durack JC, Reuter VE, Gopalan A, Gao J, Loda M, Lis RT, Bowden M, Balk SP, Gaviola G, Sougnez C, Gupta M, Yu EY, Mostaghel EA, Cheng HH, Mulcahy H, True LD, Plymate SR, Dvinge H, Ferraldeschi R, Flohr P, Miranda S, Zafeiriou Z, Tunariu N, Mateo J, Perez-Lopez R, Demichelis F, Robinson BD, Schiffman M, Nanus DM, Tagawa ST, Sigaras A, Eng KW, Elemento O, Sboner A, Heath EI, Scher HI, Pienta KJ, Kantoff P, de Bono JS, Rubin MA, Nelson PS, Garraway LA, Sawyers CL, Chinnaiyan AM. Cell. 2015 May 21;161(5):1215-28. 3. Evaluation of lactate detection using selective multiple quantum coherence in phantoms and brain tumours. Harris LM, Tunariu N, Messiou C, Hughes J, Wallace T, DeSouza NM, Leach MO, Payne GS. NMR Biomed. 2015 Jan 14. 4. Use of the temporal median and trimmed mean mitigates effects of respiratory motion in multiple- acquisition abdominal diffusion imaging. Jerome NP, Orton MR, d'Arcy JA, Feiweier T, Tunariu N, Koh DM, Leach MO, Collins DJ. Phys Med Biol. 2015 Jan 21;60(2):N9-N20. 5. Progressive computed tomography (CT) appearances preceding malignant spinal cord compression (MSCC) in men with castration-resistant prostate cancer. Pezaro C, Omlin A, Perez-Lopez R, Mukherji D, Attard G, Bianchini D, Lorente D, Parker C, Dearnaley D, de Bono JS, Sohaib A, Tunariu N. Clin Radiol. 2014 Dec 30. pii: S0009-9260(14)00287-6. 6. PTEN Protein Loss and Clinical Outcome from Castration-resistant Prostate Cancer Treated with Abiraterone Acetate. Ferraldeschi R, Nava Rodrigues D, Riisnaes R, Miranda S, Figueiredo I, Rescigno P, Ravi P, Pezaro C, Omlin A, Lorente D, Zafeiriou Z, Mateo J, Altavilla A, Sideris S, Bianchini D, Grist E, Thway K, Perez Lopez R, Tunariu N, Parker C, Dearnaley D, Reid A, Attard G, de Bono J. Eur Urol. 2014 Nov 4. pii: S0302-2838(14)01100-2. doi: 10.1016/j.eururo.2014.10.027. [Epub ahead of print] 7. Tumour responses following a steroid switch from prednisone to dexamethasone in castration-resistant prostate cancer patients progressing on abiraterone. Lorente D, Omlin A, Ferraldeschi R, Pezaro C, Perez R, Mateo J, Altavilla A, Zafeirou Z, Tunariu N, Parker C, Dearnaley D, Gillessen S, de Bono J, Attard G. Br J Cancer. 2014 Dec 9;111(12):2248-53. doi: 10.1038/bjc.2014.531. Epub 2014 Oct 14. 8. Interrogating two schedules of the AKT inhibitor MK-2206 in patients with advanced solid tumours incorporating novel pharmacodynamic and functional imaging biomarkers. Yap TA, Yan L, Patnaik A, Tunariu N, Biondo A, Fearen I, Papadopoulos KP, Olmos D, Baird R, Delgado L, Tetteh E, Beckman RA, Lupinacci L, Riisnaes R, Decordova S, Heaton SP, Swales K, deSouza NM, Leach MO, Garrett MD, Sullivan DM, de Bono JS, Tolcher AW. Clin Cancer Res. 2014 Nov 15;20(22):5672-85. doi: 10.1158/1078- 0432.CCR-14-0868. Epub 2014 Sep 19. 9. Tumour clone dynamics in lethal prostate cancer. Carreira S, Romanel A, Goodall J, Grist E, Ferraldeschi R, Miranda S, Prandi D, Lorente D, Frenel JS, Pezaro C, Omlin A, Rodrigues DN, Flohr P, Tunariu N, S de Bono J, Demichelis F, Attard G. Sci Transl Med. 2014 Sep 17;6(254):254ra125. 10. A Retrospective Study of Patients with Malignant PEComa Receiving Treatment with Sirolimus or Temsirolimus: The Royal Marsden Hospital Experience. Benson C, Vitfell-Rasmussen J, Maruzzo M, Fisher C, Tunariu N, Mitchell S, Al-Muderis O, Thway K, Larkin J, Judson I. Anticancer Res. 2014 Jul;34(7):3663-8. 11. Assessment of treatment response by total tumour volume and global apparent diffusion coefficient using diffusion-weighted MRI in patients with metastatic bone disease: a feasibility study. Blackledge MD, Collins DJ, Tunariu N, Orton MR, Padhani AR, Leach MO, Koh DM. PLoS One. 2014 Apr 12. Preclinical Evaluation of Imaging Biomarkers for Prostate Cancer Bone Metastasis and Response to Cabozantinib. Graham TJ, Box G, Tunariu N, Crespo M, Spinks TJ, Miranda S, Attard G, de Bono J, Eccles SA, Davies FE, Robinson SP. J Natl Cancer Inst. 2014 Mar 14. [Epub ahead of print] 13. Therapy monitoring of skeletal metastases with whole-body diffusion MRI. Padhani AR, Makris A, Gall P, Collins DJ, Tunariu N, de Bono JS. J Magn Reson Imaging. 2014 Feb 10. 14. Visceral disease in castration-resistant prostate cancer. Pezaro CJ, Omlin A, Lorente D, Nava Rodrigues D, Ferraldeschi R, Bianchini D, Mukherji D, Riisnaes R, Altavilla A, Crespo M, Tunariu N, de Bono JS, Attard G. Eur Urol. 2014 Feb;65(2):270-3. 15. Sarcopenia and change in body composition following maximal androgen suppression with abiraterone in men with castration-resistant prostate cancer. Pezaro C, Mukherji D, Tunariu N, Cassidy AM, Omlin A, Bianchini D, Seed G, Reid AH, Olmos D, de Bono JS, Attard G. Br J Cancer. 2013 Jul 23;109(2):325-31 16. Poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of advanced germline BRCA2 mutant prostate cancer. Sandhu SK, Omlin A, Hylands L, Miranda S, Barber LJ, Riisnaes R, Reid AH, Attard G, Chen L, Kozarewa I, Gevensleben H, Campbell J, Fenwick K, Assiotis I, Olmos D, Yap TA, Fong P, Tunariu N, Koh D, Molife LR, Kaye S, Lord CJ, Ashworth A, de Bono J. Annals Oncology (2013) 24(5):1416-1418. 17. Advanced Solid Tumours Treated with Cediranib: Comparison of Dynamic Contrast-enhanced MR Imaging and CT as Markers of Vascular Activity. Messiou C, Orton M, Ang JE, Collins DJ, Morgan VA, Mears D, Castellano I, Papadatos-Pastos D, Brunetto A, Tunariu N, Mann H, Tessier J, Young H, Ghiorghiu D, Marley S, Kaye SB, de Bono JS, Leach MO, DeSouza NM. Radiology (2012) 265(2):426-36. 18. Functional imaging: what evidence is there for its utility in clinical trials of targeted therapies?. Tunariu N, Kaye SB, deSouza NM. British Journal of Cancer (2012) 106: 619–628. 19. An evaluation of motion compensation strategies and repeatability for abdominal 1H MR spectroscopy measurements in volunteer studies and clinical trials. Germuska M, Tunariu N, Leach .O, Xu Jian, Payne G.S. NMR Biomedicine (2012) 25(6): 859-65. 20. Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies. Journal Clinical Oncology (2011) 29(10):1271-9.Yap TA, Olmos D, Brunetto A, Tunariu N, Barriuso J, Riisnaes R, Pope L, Clark J, Futreal A, Germuska M, Collins D, deSouza NM, O'Leach M, Savage RE, Waghorne C, Chai F, Garmey E, Schwartz B, Kaye SB, de Bono JS. 21. Clinical benefit of early phase clinical trial participation for advanced sarcoma patients. Cancer Chemotherapy Pharmacology (2011) 68(2):423-9. Jones RL, Olmos D, Thway K, Fisher C, Tunariu N, Postel-Vinay S, Scurr M, de Bono J, Kaye SB, Judson IR. 22. Magnetic Resonance Appearances of Uterine Malignant Mixed Mullerian Tumours (MMMT). Bharwani N, Newland A, Tunariu N, Babar S, Sahdev A, Rockall AG, Reznek RH. American Journal Roentgenology (2010) 195(5): 1268-75. 23. Ventilation-perfusion scintigraphy is more sensitive than multidetector CTPA in detecting chronic thromboembolic pulmonary disease as a treatable cause of pulmonary hypertension. Tunariu N, Gibbs JS, Win Z, Gin-Sing W, Graham A, Al-Nahhas A. Journal Nuclear Medicine (2007) 48: 680-4. 24. Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study. Wilkins MR, Paul GA, Strange JW, Tunariu N, Gibbs JS. American J Respiratory Critical Care Medicine (2005) 1. "MRI in Drug Development" - at the MSc Course in Oncology , London, July 2015. 2. "Drug toxicity, complications, pulmonary patterns, Haem-Onc Emergencies.". National Haematological Oncology Workshop Tuesday 9th June - Royal Marsden Hospital Course, London. 3. "Diffusion Weighted Imaging in lymphoma. Research directions". National Haematological Oncology Workshop Tuesday 9th June - Royal Marsden Hospital Course, London. 4. "Pitfalls of whole body MR imaging". Royal Marsden Cancer Imaging Perspectives Course - Monday 27th 5. "Choline PET scanning and whole-body diffusion-rated MRI". Prostate Cancer UK Summit 2015: Rethinking the treatment pathway. 18 April 2015, London (Janssen) 6. "Practical management: Response assessment and determining disease progression in clinical practice". Workshop at the Prostate Cancer Experience Exchange Meeting, 9-10 April 2015, Paris (Janssen) 7. "Advanced oncology: bone metastasis evaluation based on MRI DWI". Siemens sponsored workshop. ECR Vienna 4-8th March 2015. 8. "Current standards and future directions for imaging in ovarian cancer" e-grandround GR311 - 11 9. "How to use response evaluation criteria. RECIST 1.1, RANO, IWG, PCWG2, IrRC, PET EORTC, mRECIST, Choi" – RMH&ICR Biomedical Research Centre Oncological Imaging Course PET, CT, MRI, Diffusion, Key Medical and Research Aspects for Oncologists; 18 November 2014 London, UK 10. "Oncological drug induced toxicity and oncological emergencies, imaging appearances"- RMH&ICR Biomedical Research Centre Oncological Imaging Course PET, CT, MRI, Diffusion, Key Medical and Research Aspects for Oncologists; 18 November 2014 London, UK. 11. "Importance if imaging in metastatic CRPC" - 22nd PanHellenic Urological Congress 16-19 October 2014, Crete Island, Greece. 12. "Lung, CNS and musculo-skeletal targeted therapy-induced toxicity: imaging features" – ICIS (International Society of Cancer Imaging), -11 October 2014 Heidelberg, Germany. 13. "Whole body -MRI: Clinical urogenital applications" – ESUR (European Society of Urogenital Radiology) – Fall Meeting, 19 – 20 September 2014 Lisbon. 14. "What imaging should be performed pre-op in Endometrial Cancer" - British Gynaecological Cancer Society Annual Scientific Meeting, 10 - 11 July 2014,London, UK. 15. "Whole Body MRI in Oncology" - ESMOFIR – First Workshop on Clinical Functional Imaging 3-5 July 2014, Berlin, Germany. 16. "DWI for lesion detection, characterisation and response assessment – Workshop" - ESMOFIR – First Workshop on Clinical Functional Imaging 3-5 July 2014, Berlin, Germany. 17. "Imaging and Drug development: MRI – Fractional Lecturer" - MSc Oncology Experimental Cancer Pharmacology –27 June 2014, London, UK. 18. "Measuring Response to Novel Therapies: Thinking Differently". Weekend Educational Course ISMRM (International Society of Magnetic Resonance in Medicine), 10-16 May 2014, Milano, Italy. 19. "Recent developments in ovarian cancer imaging". Cancer Imaging Perspective; The 6th Royal Marsden Teaching Course, 28th April 2014, London, UK. 20. "Future directions for imaging in ovarian cancer". Roche National educational meeting on Advanced Ovarian Cancer, 4-5 April 2014, London, UK. 21. "Is there a better way to image mesothelioma than CT?" - 12th Annual BTOG Conference 29th -31st January 2014 Dublin, Ireland. 22. "Importance of Imaging in CRPC" – Emerging treatment options in mCRPC Zytiga Satellite Symposium, Hellenic at the Urological congress, 15 November 2013, Athens, Greece. 23. "Pattern of Spread of Abdominal Malignancy" - London Deanery Part 2 FRCR Teaching Course ‘Oncological Imaging' 5 November 2013, London, UK. 24. "Response evaluation criteria: RECIST, RECIST 1.1, functional imaging response criteria, in the clinical/research setting" – RMH Oncological Imaging Course: PET, CT, MRI, Diffusion, Key Medical and Research Aspects for Oncologists 25. "Complications of Targeted Therapies" – ICIS 2013, 30th September – 2nd October 2013; York, UK 26. "GBCA in Cancer Imaging" - The use of GBCA in MRI: Safety & Efficacy Seminar 19 October 2013, Bath, UK 27. "Essentials in Imaging for Oncologists" – 12th ESO-ESMO Masterclass in Clinical Oncology, 16-21 March 2013, Ermatingen (Lake Constance), Switzerland. 28. "The Role of MRI in Gynaecological Malignancies" - Everything you ever wanted to know about gynaecological cancer imaging RMH Course – 9 March 2013, London, UK. 29. "Metastatic prostate cancer – beyond the bone scan" at the Educational Meeting "Shattering the Silence - Redefining expectations in Metastatic Castrate Resistant Prostate Cancer (mCRPC)", 23 November 2012, Dublin, Ireland. 30. "Imaging of ovarian cancer (can we pre-operatively predict resectability?)" – South East Gynae- Oncology Group Meeting, 2 November 2012, Maidstone, UK. 31. "Imaging in Drug Development" at Researchers for the future 2012/2013 "Forscher für die Zukunft 2012/2013" - German Radiology trainees meeting, 25-26 October 2012, Heidelberg, Germany. 32. "MDM multimodality— clinical cases discussion and debate" - Oncological Imaging – PET, CT, MRI, Diffusion What all Oncologist Need to know Course, 12March 2012, London, UK. 33. "Pattern of Spread of Abdominal Malignancy" London Deanery Part 2 FRCR Teaching Course ‘Oncological Imaging', 7 February 2012, London, UK. 34. "Future prospective of multiparametric functional imaging" - Non-Conventional Imaging in Oncology Symposium, June 30 - 2nd July 2011, Milano, Italy. 35. Developing and refining multiparametric MRI as a response biomarker to monitor the mechanism of action of novel anti-cancer therapies. "MD presentation day" – 15th June 2009, Institute of Cancer Prezentari Orale La Conferinte De Specialitate 1. Lopez RP, Lorente D, Mateo J, Blackledge MD, Sideris S, Zafeiriou Z, et al. 797 Prognostic relevance of imaging bone metastases by whole body diffusion-weighted magnetic resonance imaging (WBDWI) in metastatic castration-resistant prostate cancer (mCRPC). Annals of Oncology. 2014;25(suppl 4):iv276. 2. Rata M, Tunariu N, Koh DM, de Bono, JS, Leach MO, Collins DJ; Blackledge MD, Whole Body Quantitative MultiParametric Characterisation of tumour heterogeneity for response evaluation ISMRM 21th Annual Scientific Meeting & Exhibition, Salt Lake City. Proc Intl Soc Mag Reson Med 21 (2013); abstract 592. 3. Rata M, Collins DJ, d'Arcy JA, Messiou C, Tunariu N, Leach MO, de Souza NM, Orton MR. Evaluation of Reproducibility of Measured Arterial Input Functions and DCE-MRI Derived Model Estimates Obtained Using Either Pre-Bolus Individual AIF's or Population Derived AIF's. ISMRM 20th Annual Scientific Meeting & Exhibition, Melbourne. Proc Intl Soc Mag Reson Med 21 (2013); abstract 0237. 4. de Bono JS, Smith MR, Rathkopf D, Corn PG, Mukherji D, Harzstark AL, Sartor OA, Smith DC, Tunariu N, Sweeney C. Cabozantinib (XL184) at 40 mg in patients with metastatic castration resistant prostate cancer (mCRPC): results of a phase 2 Non-randomized Expansion cohort (NRE) Abstract Book of the 37th ESMO Congress Vienna, Austria, 28 September – 2 October 2012. 5. Yap TA, Yan L, Patnaik A, Olmos D, Fearen I, Baird RD, Papadopoulos KP, Tunariu N, Biondo A, H. Keilhack H, Delgado LM, Taylor A, Blackman SC, Carpenter CL, Decordova S, Heaton S, Garrett MD, Sullivan D, de Bono JS, Tolcher AW. Final results of a translational phase l study assessing a QOD schedule of the potent AKT inhibitor MK-2206 incorporating predictive, pharmacodynamic (PD), and functional imaging biomarkers. ASCO Annual Meeting Proceedings, Journal Clinical Oncology, 29 (2011); abstract 3001. 6. Yap T, Patnaik A, Fearen I, Olmos D, Papadopoulos D, Tunariu N, Sullivan D, Yan D, De Bono JS, Tolcher AS. First-in-class phase I trial of a selective Akt inhibitor, MK2206 (MK), evaluating alternate day (QOD) and once weekly (QW) doses in advanced cancer patients (pts) with evidence of target modulation and antitumor activity. Journal of Clinical Oncology, 2010 ASCO Annual Meeting Proceedings, 28-15: 3009. 7. Tunariu N, Taylor NJ, Ah-See ML, Stirling JJ, Makris A, d'Arcy JA, Collins D, Padhani AR. Improving reproducibility of DCE-MRI by altering arterial input function does not improve test performance for predicting outcomes of breast cancer treated with chemotherapy - "Hot Topics in Cancer Imaging" competition Joint Annual Meeting ISMRM-ESMRMB 19-25 May 2007 Proc. Intl. Soc. Mag. Reson. Med. 15 (2007); abstract 2828. 8. Tunariu N, Gibbs JS, Win Z, Gin-Sing W, Graham A, Al-Nahhas A; V/Q scans are more sensitive than CTPA in detecting chronic thromboembolic disease as a cause of Pulmonary Hypertension; abstract nominated for the Marie Curie Award and presented in the Highlight Lecture. European Association of Nuclear Medicine Proceedings, Athens 2006. 9. Tunariu N, Gibbs JS, Win Z, Gin-Sing W, Graham A, Al-Nahhas A. V/Q scans are more sensitive than CTPA in detecting chronic thromboembolic disease as a cause of Pulmonary Hypertension. Romanian Nuclear Medicine Annual Proceedings, Bucharest 2006. 10. Tunariu N, Sfrangeu S. Radiological and Medico-Surgical Correlation in the Chronic Arteriosclerosis of the Lower Limbs – Licence Thesis; September 1997, Cluj Napoca, Romania; awarded 1st class Carti Medicale – co-autor 1. Focal Therapy in Prostate Cancer. Editors: Dr Hashim U Ahmed, Dr Manit Arya , Professor Peter Carroll , Dr Mark Emberton. Chapter: Diffusion Weighted Imaging for Prostate Cancer. Riches S, Tunariu N, de Souza NM 2. "Ghid Practic de Diagnostic si Conduita in Obstetrica" – Practical Guide for Diagnostic and Management in Obstetrics. Editura C2 design, Brasov 2000, Romania. Moga M, Nanu D, Anastasiu C, Tunariu N. 3. "Course in Diagnostic and Conduit in Obstetrics Therapy" - Curs de Diagnostic si Atitudine Terapeutica Obstetricala; Brasov-Print, 1999, Romania. Moga M, Nanu D, Anastasiu C, Tunariu N, Angelescu S. Afilieri Profesionale Royal College of Radiologists General Medical Council UK International Cancer Imaging Society (ICIS) European Society of Radiology (ESR) Europeans Society Molecular and Functional Imaging in Radiology European Society of UroGenital Radiology International Society for Magnetic Resonance in Medicine (ISMRM) Radiological Society of North America (RSNA) American Association of Cancer Research (AACR) Medical Defence Unit (MDU) European Society Medical Oncology (ESMO) Experimental Cancer Meeting Centre (ECMC) Network Cursuri si Conferinte Annual Conferences and Educational Courses FLIMS workshop 22-28 June 2013 International Society of Magnetic Resonance in Medicine (ISMRM) – Annual Meetings & Weekend Educational Courses – annual attendance April 2007 – 2013 Experimental Cancer Medicine Centres (ECMC) Annual Network Meetings - May - annually 2010 - 2013 Institute of Cancer Research Annual Conference June 2011 & 2012 American association Cancer Research (AACR) - April 2013 International Cancer Imaging Society (ICIS) – October 2009 & 2012 Master Class in Oncology ESMO Course – March 2012 Royal College of Radiology (RCR) International Day of Radiology Blue Skies Session November 2012 ESMRMB School of MRI -Body Diffusion-weighted MR Imaging: From Theory to Practice April 2012, London American Society Clinical Oncology (ASCO) – June 2011 22nd International LH Gray Conference - Realising the potential of drug–radiation interactions in cancer treatment February 2011 Manchester, UK International course of DCE-US, April 2010, Paris Imaging in Drug Development – March 2010 London, organised by SMi Group (CPD Accredited) Annual Congress of the European Association of Nuclear Medicine (EANM) October 2009
January 2013 Medications Requiring Prior Authorization for Medical Necessity Below is a list of medicines by drug class that will not be covered without a prior authorization for medical necessity, effective January 1, 2013. If you continue using one of these drugs after this date without prior approval, you may be required to pay the full cost.